Especially in high glycolytic cancers, such as MYC-driven cancers, MCT1 facilitates lactate uptake and PD-1 expression in Tregs, a novel mechanistic view of anti-PD-1 therapy resistance (Kumagai et al., 2022). The gene discussed is MYC; the disease is cancer.